B+
Bull case
20%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
IBIO
iBioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
iBio exited FY2026 with a clinical-stage pipeline, near-completion of IBIO-600 single-ascending-dose testing, additional IND-enabling programs, and management-reported cash runway into fiscal 2028. Successful IBIO-600 escalation or credible early clinical signals could materially improve investor confidence [#SEC-8K-2026-08-28].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional equity issuance, including the Jefferies facility for up to $100 million of common stock, creates dilution risk [#SEC-8K-2026-08-28].
Momentum
96
Value
59
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.35 · Bull $2.10 · Bear $0.70Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-28 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.53
Why
Momentum96 · Δ7d -
Value59 · Δ7d 0.0
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Additional equity issuance, including the Jefferies facility for up to $100 million of common stock, creates dilution risk [#SEC-8K-2026-08-28].
- • FY2026 revenue was approximately $0.1 million against a $33.0 million net loss, with R&D expense increasing to approximately $19.6 million [#SEC-8K-2026-08-28].
- • The company remains effectively pre-revenue and early clinical: FY2026 revenue was approximately $0.1 million, net loss was $33.0 million, and R&D expense rose to $19.6 million.
Catalyst clock
2026-12-03
Post-print repricing of FY2026 clinical transition
Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
69
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.6 / Value 58.9 / Sentiment 69.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-28
Fundamentals (TTM)
As of 2026-08-28
Market Cap
$72.03M
Beta
1.26
Shares Out
49.68M
P/E (TTM) · Derived
-4.6
P/S (TTM)
84.55
P/FCF (TTM) · Derived
-2.91
Rev YoY
-100.0%
EPS YoY
-86.9%
Gross Margin
-255.0%
Op Margin
-4089.4%
Net Debt
-$5.07M
Current Ratio
11.88
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data